Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

Source

GlaxoSmithKline, Research Triangle Park, North Carolina, USA.

Abstract

Up to 25% of patients diagnosed with breast cancer have tumors that overexpress HER2. HER2-positive breast cancer is highly proliferative, difficult to treat, and confers a poor prognosis. The advent of the anti-HER2 monoclonal antibody trastuzumab (Herceptin) has markedly altered the clinical course of both early and advanced HER2-driven breast cancer. Despite the use of trastuzumab, however, patients with HER2-positive breast cancer still experience disease progression. Overcoming that resistance to therapy is our next challenge. This review examines the current understanding of HER2 biology, the mechanisms of action of and resistance to trastuzumab, as well as new therapies on the horizon.

PMID:: 17263127; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

Progression and treatment of HER2-positive breast cancer. [Cancer Chemother Pharmacol. 2010]
Progression and treatment of HER2-positive breast cancer.
Davoli A, Hocevar BA, Brown TL. Cancer Chemother Pharmacol. 2010 Mar; 65(4):611-23. Epub 2009 Dec 20.
Review Her2-positive breast cancer: herceptin and beyond. [Eur J Cancer. 2008]
Review Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W, Esteva FJ. Eur J Cancer. 2008 Dec; 44(18):2806-12. Epub 2008 Nov 18.
Review [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. [Orv Hetil. 2001]
Review [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M. Orv Hetil. 2001 Nov 18; 142(46):2563-8.
Review Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. [Semin Oncol. 1999]
Review Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S. Semin Oncol. 1999 Aug; 26(4 Suppl 12):71-7.
Review Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. [Drugs. 2006]
Review Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL, Keam SJ. Drugs. 2006; 66(4):449-75.

See reviews... See all...

Cited by 1 PubMed Central article

Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. [Nucl Med Biol. 2009]
Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
Vaidyanathan G, Jestin E, Olafsen T, Wu AM, Zalutsky MR. Nucl Med Biol. 2009 Aug; 36(6):671-80.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Protein Clusters
Clusters of related proteins from the Protein Clusters database that cite the current articles. Sources of references in Protein Clusters include the associated Gene and Conserved Domain records as well as NCBI added citations.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Domains
Conserved Domain Database (CDD) records that cite the current articles. Citations are from the CDD source database records (PFAM, SMART).
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive bre...
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Oncology (Williston Park). 2006 Dec ;20(14):1763-71; discussion 1771-2, 1774-6.

PubMed
Reducing hospital standardized mortality rate with early interventions.
Reducing hospital standardized mortality rate with early interventions.
J Trauma Nurs. 2006 Oct-Dec ;13(4):178-82.

PubMed
A survey of PDA use by palliative medicine practitioners.
A survey of PDA use by palliative medicine practitioners.
J Palliat Care. 2006 Winter ;22(4):267-74.

PubMed
From tangles to tau protein.
From tangles to tau protein.
Bratisl Lek Listy. 2006 ;107(9-10):341-2.

PubMed
X-linked NDUFA1 gene mutations associated with mitochondrial encephalomyopathy.
X-linked NDUFA1 gene mutations associated with mitochondrial encephalomyopathy.
Ann Neurol. 2007 Jan ;61(1):73-83.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: